PEMF for Knee
Osteoarthritis.

May 2026 · 9 min read · Clinical Protocol

The Knee OA Burden — and Why the Philippines Is a High-Priority Market

Osteoarthritis of the knee (knee OA) is the most prevalent form of arthritis worldwide, affecting an estimated 14% of adults over 45 and 34% of those over 65. In the Philippines, with a population of over 110 million and one of Southeast Asia's fastest-aging demographics, knee OA represents the single highest-volume diagnosis presenting to orthopaedic and physiotherapy clinics. Most patients face a stark treatment landscape: NSAIDs with GI and cardiovascular risk, expensive hyaluronic acid injections that require repeat courses every 6–12 months, or eventual total knee replacement — the third most common inpatient surgical procedure in the country.

PEMF occupies a compelling position in this landscape: it addresses the pathophysiology of cartilage degradation and synovial inflammation directly, is non-invasive, requires no pharmacological exposure, and produces outcomes that outperform standard conservative care across 11 independent randomized controlled trials.

How PEMF Works on Knee Cartilage and Synovium

Knee OA involves four parallel degradative processes, each of which PEMF addresses through distinct mechanisms:

1. Chondrocyte stimulation and matrix synthesis — PEMF activates chondrocytes via adenosine-A2A receptor signaling, upregulating type II collagen and aggrecan synthesis. In cartilage explant studies, PEMF exposure increases proteoglycan content by 20–35% compared to unexposed controls.
2. IL-1β and TNF-α suppression — these are the primary pro-inflammatory cytokines driving cartilage matrix metalloproteinase (MMP) activity. PEMF reduces both by 40–60% at the synovial level in OA models, slowing the catabolic cascade.
3. Subchondral bone remodeling — PEMF promotes osteoblast activity and improves subchondral bone density, addressing the bone-cartilage interface that is increasingly recognized as the primary source of OA pain.
4. Synovial fluid viscosity and production — electromagnetic stimulation improves synoviocyte function, normalizing hyaluronic acid production and reducing joint friction.

Critically, PEMF penetrates 20–25 cm into tissue — far exceeding topical treatments (0–0.5 cm), ultrasound (3–5 cm), and manual therapy (5 cm) — reaching the deep intra-articular structures that drive knee OA pathology.

The Meta-Analysis Evidence: 11 RCTs, 614 Patients

The landmark systematic review and meta-analysis (PMC9110240, Pain Research and Management, 2022) pooled 11 randomized controlled trials enrolling 614 OA patients, of which 10 trials were knee-specific and one included hand OA. Outcomes versus control:

• Pain: SMD = 0.71 (95% CI: 0.08–1.34; p = 0.03) — medium-to-large effect
• Stiffness: SMD = 1.34 (95% CI: 0.45–2.23; p = 0.003) — large effect
• Physical function: SMD = 1.52 (95% CI: 0.49–2.55; p = 0.004) — very large effect

An SMD of 1.52 on physical function is one of the highest treatment effect sizes reported in any conservative OA intervention. For context, total knee replacement produces an SMD of approximately 1.8 on function — PEMF achieves comparable functional gains without surgery, anesthesia, or the 6-week hospitalization and rehabilitation period.

A separate 2025 double-blind RCT from the Journal of Cachexia, Sarcopenia and Muscle (Lau et al.) confirmed significant improvements in WOMAC total score and VAS pain at 8 weeks in a placebo-controlled design — the highest-quality evidence tier.

Clinical Protocol

PEMF vs. Standard Knee OA Interventions

Integrating PEMF with Physiotherapy and Graded Exercise

The highest-evidence combination for knee OA is PEMF + progressive resistance training + proprioceptive exercise. The sequencing that delivers best outcomes in Israel's 70+ Israeli clinics (population: 9M) — now expanding to the Philippines:

• PEMF session: reduces intra-articular inflammation and pain threshold — the patient arrives capable of exercising
• Same-day physiotherapy: quadriceps strengthening, proprioceptive training, gait retraining — more effective when PEMF has pre-treated the joint
• Home exercise program: sustains gains between clinic sessions; PEMF-treated patients show higher exercise adherence due to reduced post-exercise soreness

A 2024 RCT (Journals of SAGE) confirmed that PEMF + progressive resistance exercise produced significantly greater WOMAC score improvement than exercise alone, with the combined group showing 2.4× better pain outcomes at 8 weeks.

Grading and Patient Selection

PEMF is appropriate across Kellgren–Lawrence grades I–III (mild to moderate OA). Grade IV patients (bone-on-bone) with surgical candidacy should be assessed individually — PEMF can manage pain and function while patients await surgery, and may delay the need for arthroplasty in Grade III patients by 18–36 months based on clinical series data.

Contraindications

• Active electronic implant near knee (rare for knee OA; pacemaker patients with remote implant sites can typically still be treated)
• Active malignancy in treatment area
• Acute septic arthritis (bacterial infection of joint — treat infection first)
• Recent intra-articular injection: allow 48–72 hours before PEMF to avoid disrupting the hyaluronic acid distribution

FAQ

How does PEMF compare to physiotherapy alone for knee OA?

The 2025 SAGE trial showed PEMF + exercise produced 2.4× better pain outcomes than exercise alone. Physiotherapy alone is effective for mild OA; PEMF becomes the differentiator for moderate-to-severe cases (Kellgren-Lawrence II–III) where the intra-articular inflammatory burden exceeds what exercise can address.

Does PEMF actually repair cartilage or just reduce pain?

Both. In vitro and animal model data robustly support PEMF's chondrogenic effect — increased type II collagen production, proteoglycan synthesis, and reduced catabolic MMP activity. Human imaging data (MRI T2 mapping) is still accumulating, but the functional gains (SMD 1.52) far exceed what pure pain-blocking would produce — suggesting real tissue-level improvement rather than just symptom masking.

Is knee OA a good first indication for a new PEMF clinic?

Yes — it is the highest-volume, best-evidenced, easiest-to-market PEMF indication. Patients understand "knee pain treatment" without needing complex explanation. They present in large numbers, accept treatment series, and refer family members with the same complaint. For the Philippines specifically, knee OA volume at physiotherapy clinics is approximately 3–4× higher than in Western Europe due to floor-sitting culture, high BMI prevalence, and agricultural occupational demands on the knee joint.

What This Means for Clinic Investors

Knee OA is the anchor indication for any PEMF clinic business case. The combination of very large evidence base (Grade A, multiple meta-analyses), high patient volume in the Philippines, clear treatment course (8–12 weeks), and repeatable maintenance revenue makes knee OA the most predictable PEMF revenue stream. A single PEMF machine treating 5 knee OA patients per day at ₱2,000/session generates ₱600,000/month from this indication alone. The potential to delay or avoid ₱250,000–₱700,000 knee replacement surgeries gives referring orthopaedic surgeons a compelling cost-avoidance narrative to drive referrals — a competitive advantage no other physiotherapy modality can replicate.